InMed Pharmaceuticals INM Institutional Ownership

Ownership Summary

InMed Pharmaceuticals Inc. (NASDAQ:INM) appears in 9 institutional 13F filings for the quarter ending March 2026.

• These investors collectively held 7.9% of InMed Pharmaceuticals's outstanding shares in March 2026, up from 5.7% in December 2025.
• They increased total shares held in InMed Pharmaceuticals by 57.82% from the prior quarter, while the number of investors in INM increased 50.0% year over year.
• Of these 9 funds, 6 grew their exposure to InMed Pharmaceuticals, 0 cut back, and 3 maintained positions.
• In total, institutional investors held 319.31K shares in InMed Pharmaceuticals as of March 2026, up by 116.99K shares quarter on quarter, and up 312.89K shares year over year.
• As of March 31, 2026, the biggest holder of InMed Pharmaceuticals is SABBY MANAGEMENT, LLC at 220.26K shares, representing 5.44% of shares outstanding.
• Top purchasers of INM stock for the quarter ending March 2026 included CITADEL ADVISORS LLC (46.97K), Virtu Financial LLC (19.98K), TWO SIGMA SECURITIES, LLC (18.72K), SABBY MANAGEMENT, LLC (18.63K), UBS Group AG (7.69K).
• According to Business Quant data, leading holders of INM for March 2026 are SABBY MANAGEMENT, LLC (220.26K), CITADEL ADVISORS LLC (46.97K), Virtu Financial LLC (19.98K), TWO SIGMA SECURITIES, LLC (18.72K), UBS Group AG (8.07K), Private Wealth Management Group, LLC (5.0K), SBI Securities Co., Ltd. (300), Banque Cantonale Vaudoise (6), Federation des caisses Desjardins du Quebec (1).